Pyxis Oncology Files 8-K for Other Events
Ticker: PYXS · Form: 8-K · Filed: 2024-03-27T00:00:00.000Z
Sentiment: neutral
Topics: 8-K, SEC Filing, Disclosure
TL;DR
Pyxis Oncology filed an 8-K. No major news, just standard reporting.
AI Summary
Pyxis Oncology, Inc. filed an 8-K on March 27, 2024, to report other events and financial statements. The filing does not detail specific transactions or financial results but serves as a notification of these items being filed.
Why It Matters
This filing indicates Pyxis Oncology is making material disclosures to the SEC, which could include significant corporate events or financial updates relevant to investors.
Risk Assessment
Risk Level: low — The filing is a standard procedural disclosure and does not contain information about significant negative events.
Key Numbers
- 20240327 — Report Date (Date of the earliest event reported)
Key Players & Entities
- Pyxis Oncology, Inc. (company) — Registrant
- 001-40881 (company) — Commission File Number
- 83-1160910 (company) — IRS Employer Identification No.
- 321 Harrison Avenue, Boston, Massachusetts 02118 (company) — Principal Executive Offices Address
- 617-221-9059 (company) — Registrant's Telephone Number
FAQ
What specific 'Other Events' are being reported by Pyxis Oncology?
The provided text does not specify the details of the 'Other Events' beyond listing it as an item information category.
When was this 8-K filing submitted to the SEC?
The filing was submitted on March 27, 2024.
What is the Commission File Number for Pyxis Oncology?
The Commission File Number for Pyxis Oncology is 001-40881.
Where are Pyxis Oncology's principal executive offices located?
Pyxis Oncology's principal executive offices are located at 321 Harrison Avenue, Boston, Massachusetts 02118.
Does this filing contain detailed financial statements?
The filing lists 'Financial Statements and Exhibits' as an item information category, but the provided text does not include the content of these statements.
Filing Stats: 509 words · 2 min read · ~2 pages · Grade level 12.5 · Accepted 2024-03-27 07:49:14
Key Financial Figures
- $0.001 — ch registered Common Stock, par value $0.001 per share PYXS The Nasdaq Global Se
- $8 million — er asset for a one-time cash payment of $8 million. Additionally, all royalties previously
Filing Documents
- pyxs-20240327.htm (8-K) — 40KB
- pyxs-ex99_1.htm (EX-99.1) — 16KB
- img244827169_0.jpg (GRAPHIC) — 7KB
- 0000950170-24-036822.txt ( ) — 184KB
- pyxs-20240327.xsd (EX-101.SCH) — 25KB
- pyxs-20240327_htm.xml (XML) — 5KB
01 Other Events
Item 8.01 Other Events. On March 27, 2024, Pyxis Oncology, Inc. (the "Company") issued a press release announcing that the Company entered into an agreement with Novartis Technology LLC ("Novartis") for the sale of its rights to royalties from the commercialization of Beovu (brolucizumab-dbll) and another asset for a one-time cash payment of $8 million. Additionally, all royalties previously received by Apexigen, Inc. ("Apexigen") and the Company from Novartis will be free from any reclaim rights. In August 2023, the Company completed the acquisition of Apexigen and assumed all out-licensing agreements of Apexigen, including rights to royalties on sales of Beovu and another asset discovered using the APXiMAB Platform, Apexigen's proprietary antibody discovery platform. A copy of this press release is attached as Exhibit 99.1 to this Current Report on Form 8-K.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release dated March 27, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. Pyxis Oncology, Inc. Date: March 27, 2024 By: /s/ Pamela Connealy Pamela Connealy Chief Financial Officer and Chief Operating Officer